枸橼酸舒芬太尼(Sufentanil Citrate) - 药物靶点：Opioid receptors_在研适应症：急性疼痛，疼痛，麻醉_专利_临床

概要

基本信息

药物类型

小分子化药

别名

sufentanil、Sufentanil citrate (USP)、Sufentanil TDS (free base)

+ [14]

靶点

Opioid receptors

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Laboratoire Aguettant SAS

Vertical Pharmaceuticals LLC

宜昌人福药业有限责任公司

+ [1]

非在研机构

FGK Representative Service GmbH

Talphera, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1984-05-04),

麻醉阴道分娩过程

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C28H38N2O9S

InChIKeyOJCZPLDERGDQRJ-UHFFFAOYSA-N

CAS号60561-17-3

关联

110

项与枸橼酸舒芬太尼相关的临床试验

NCT06530563 / Not yet recruiting临床4期IIT

the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery: a Randomized, Double-blind, Positive-drug Parallel-controlled, Multi-center Clinical Study

The goal of this clinical trial is to learn if Oliceridine fumarate injection works to treat acute pain after abdominal surgery. It will also learn about the safety of Oliceridine fumarate injection. The main questions it aims to answer are:
1. Does Oliceridine fumarate injection works to treat acute pain after abdominal surgery?
2. Does Oliceridine fumarate injection lead to less adverse effect?
Researchers will compare Oliceridine fumarate injection to a positive-drug (Sufentanil Citrate) to see if Oliceridine fumarate injection not inferior to sufentanil in the efficacy and safety for acute pain after abdominal surgery.
Participants will:
1. Receive patient controlled analgesia treat using Oliceridine or sufentanil after surgery
2. Be followed up every 6 hours until 48 hours after surgery or before discharge

开始日期2024-08-01

申办/合作机构

中南大学湘雅医院

NCT06388408 / CompletedN/AIIT

Effects of Sufentanil Delivered With Target Controlled Infusion (TCI) on Patient State Index Values, Electroencephalographic Spectrum and Analgesia Nociception Index During Total Intravenous Anesthesia With Propofol TCI

Sufentanil Target Controlled infusion (TCI, Gepts model) effects on Neuromonitoring during Total Intravenous Anesthesia (TIVA) with Propofol TCI (Eleveld model) has not been investigate yet.
Authors aim to investigate its effect on Patient State index (PSi), the power spectrum EEG, the Analgesia Nociception Index (ANI) nad pupillometry values during maintenance durin TIVA-TCI with Propofol and Sufentanil.

开始日期2024-05-05

申办/合作机构

University of Padua

NCT05957653 / Not yet recruiting临床4期IIT

Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort After Robot-assisted Radical Prostatectomy: a Randomized, Double-blind, Controlled Trial

The goal of this clinical trial is to evaluate the incidence and severity of postoperative catheter-related bladder discomfort after robot-assisted radical prostatectomy.
The main question it aims to answer is to evaluate incidence of CRBD immediately after extubation in resuscitation.
A total of 20ml of 2% lidocaine and 1μg/ml sufentanil or 20ml normal saline was injected into the bladder of the participants through the catheter. After drug injection, the catheter was clamped for 20 minutes, and then 100ml normal saline was injected into the bladder through the catheter to flush out.
Then, the incidence of CRBD was compared between the two groups.

开始日期2023-10-07

申办/合作机构

上海交通大学医学院附属仁济医院

100 项与枸橼酸舒芬太尼相关的临床结果

登录后查看更多信息

100 项与枸橼酸舒芬太尼相关的转化医学

登录后查看更多信息

100 项与枸橼酸舒芬太尼相关的专利（医药）

登录后查看更多信息

60

项与枸橼酸舒芬太尼相关的文献（医药）

2024-04-10·Videosurgery and Other Miniinvasive Techniques

Comparison of low and standard pneumoperitoneum pressure in laparoscopic pediatric inguinal hernia repair

Article

作者: Lyu, Yunxiao ; Chen, Liang

Introduction:

The effectiveness and safety of low pneumoperitoneum in laparoscopic pediatric inguinal hernia repair is unclear and required to explore.

Aim:

To evaluate the benefits of low (LPP) vs. standard pneumoperitoneum pressure (SPP) in laparoscopic pediatric inguinal hernia repair.

Material and methods:

We performed a retrospective cohort analysis of patients with pediatric inguinal hernia. The patients were divided into LPP and SPP groups. Anesthesia and postoperative characteristics were analyzed.

Results:

We enrolled 169 eligible patients in this study. Anesthesia and postanesthesia care unit times in the LPP group were lower than those in the SPP group (p = 0.00, p = 0.01, respectively). The LPP group had lower values for peak partial pressure of end-tidal carbon dioxide (P_ETCO₂; mm Hg) (33.37 ±4.09 vs. 36.56 ±4.08), trough P_ETCO₂ (38.33 ±5.04 vs. 40.46 ±4.14), and P_ETCO₂ at the end of surgery (35.29 ±4.59 vs. 38.76 ±4.22). The LPP group required less sufentanil citrate (8.76 ±4.07 ml vs. 18.03 ±16.04 ml) and midazolam (1.56 ±0.45 ml vs 1.79 ±0.59 ml) vs. the SPP group, respectively. There was no significant difference between the groups regarding postoperative complications.

Conclusions:

LPP was associated with shorter anesthesia and postanesthesia care unit times, and lower P_ETCO₂ values compared with SPP. Compared with the SPP group, the LPP group had comparable operation times and postoperative complications. However, long-term outcome studies are needed.

2024-01-12·Zhongguo zhen jiu = Chinese acupuncture & moxibustion

Effect of acupuncture at Shuitong and Shuijin points on sufentanil-induced cough in general anesthesia induction: a randomized controlled trial.

Article

作者: Xu, Jiping ; Li, Peng ; Ji, Jiafu ; Su, Fan ; Hu, Lihua

OBJECTIVES:

To observe the therapeutic effect of acupuncture at Shuitong and Shuijin points on preventing sufentanil-induced cough and its influence on hemodynamics in general anesthesia induction.

METHODS:

A total of 80 patients scheduled for elective surgery undergoing general anesthesia were randomly divided into an observation group (40 cases) and a control group (39 cases,1 case eliminated). In the control group, the routine anesthesia was performed,with intravenous injection of 1% sufentanil citrate 0.5 μg/kg, 1% propofol (total amount was calculated according to 2 mg/kg) and cisatracurium besilate 0.2 mg/kg. In the observation group, before routine anesthesia induction, acupuncture was applied to Shuitong and Shuijin points on the right and the needles were retained for 30 min. During anesthesia induction, the complications i.e. cough and chest wall stiffness were observed, and the systolic blood pressure (SBP), heart rate (HR) and pulse oxygen saturation (SpO₂) were monitored 5 min after the patients entered the operation room (T₀),at the moment of intravenous injection of sufentanil (T₁) and 2 min after sufentanil injection (T₂) , 1 min before and after endotracheal intubation (T₃,T₄) of the two groups, respectively.

RESULTS:

During anesthesia induction,the condition of mild, moderate and severe cough in the observation group was superior to that of the control group (P<0.05), the total cases of cough and its total incidence were lower than those of the control group (P<0.05). Two cases of chest wall stiffness were present in each group, but without statistical difference between the two groups (P>0.05). In comparison of SBP, HR and SpO₂ at T₀, T₁, T₂, T₃ and T₄, the differences were not significant statistically between the two groups (P>0.05). SBP and HR increased at T₂ when compared with those at T₁ in the control group (P<0.05), but there was no statistical difference in SpO₂ (P>0.05); while, the differences in SBP, HR and SpO₂ were not significant at T₂ when compared with those at T₁ in the observation group (P>0.05).

CONCLUSIONS:

Acupuncture at Shuitong and Shuijin points can effectively prevent from sufentanil-induced cough, reduce the severity of cough and stabilize the hemodynamic indicators.

2023-05-01·Applied spectroscopy

Quantitative Raman Cross-Sections and Band Assignments for Fentanyl and Fentanyl Analogs

Article

作者: Kline, Neal D. ; Wilcox, Phillip G. ; Pardoe, Ian J. ; Emmons, Erik D. ; Guicheteau, Jason A.

Raman cross sections and spectra were measured for five synthetic opioid fentanyl analogs: fentanyl citrate, sufentanil citrate, alfentanil HCl, carfentanil oxalate, and remifentanil HCl. The measurements were performed with excitation wavelengths in the visible (532 nm) and near infrared (785 nm). In addition, density functional theory (DFT) calculations were employed to generate simulated spectra of the compounds and aid in identification of the observed spectral modes. These cross-section measurements and calculations were also used to assess results from a series of measurements of fentanyls cut with other powdered materials. These measurements are valuable for assessment of field-deployable Raman chemical sensors for detection of fentanyl and fentanyl analogs, including when mixed with other materials.

53

项与枸橼酸舒芬太尼相关的新闻（医药）

2024-10-22

·药融云

35亿+麻醉剂，恩华药业拿下！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月21日，据NMPA官网公示，江苏恩华药业提交的注射用盐酸瑞芬太尼新适应症获批上市并视同通过一致性评价，适应症为重症监护患者机械通气时的镇痛。据摩熵医药（原药融云）数据库显示，该品种在2023年全国院内市场的销售额超35亿元。截图来源：NMPA官网注射用盐酸瑞芬太尼是一款μ阿片类受体激动剂，被广泛用于胸外科手术、泌尿外科手术等各种手术中的全麻诱导和全麻中维持镇痛，具有起效快、作用时间短、镇痛效价强等优势。据摩熵医药（原药融云）数据库显示，注射用盐酸瑞芬太尼在2023年全国院内市场的销售额超35亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库目前，国内仅有人福医药、国药工业、恩华药业3家企业拥有注射用盐酸瑞芬太尼的生产批文并通过仿制药一致性评价。截图来源：摩熵医药（原药融云）过评药品汇总截至目前，江苏恩华药业有咪达唑仑注射液、奥赛利定富马酸盐注射液、枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼等28款品种过评，其中有10款品种为首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

一致性评价上市批准医药出海

2024-09-23

·GlobeNewswire-Health Care

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestones MIPLYFFA™ is now the sixth commercial asset in XOMA Royalty’s portfolio EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today Zevra Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for MIPLYFFA™ (arimoclomol). MIPLYFFA™ is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients two years of age and older. It is the sixth commercial asset in XOMA Royalty’s growing royalty and milestone portfolio. “With the approval of MIPLYFFA™, NPC patients in the United States now have access to the first FDA approved therapeutic in this rare, progressive and fatal neurodegenerative disease,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Based on the clinical data to date, we believe MIPLYFFA™ plus miglustat has the potential to improve outcomes and slow disease progression for many NPC patients.” In June 2023, XOMA Royalty announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol’s commercial sales and up to $52.6 million, net, in potential milestone payments from Zevra. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the amount of potential milestone and commercial payments to XOMA Royalty and other developments related to MIPLYFFA™ (arimoclomol), and the potential of XOMA Royalty’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, and our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor Contact Media ContactJuliane SnowdenKathy VincentXOMA Royalty CorporationKV Consulting & Management+1 646-438-9754+1 310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

上市批准

2024-09-23

·GlobeNewswire-Health Care

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor ContactJuliane SnowdenXOMA Royalty Corporation+1 646-438-9754juliane.snowden@xoma.comMedia ContactKathy VincentKV Consulting & Management+1 310-403-8951kathy@kathyvincent.com

100 项与枸橼酸舒芬太尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00845	枸橼酸舒芬太尼	N01AH03	DB00708

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性疼痛	美国	Vertical Pharmaceuticals LLC	2018-11-02
疼痛	欧盟	Laboratoire Aguettant SAS	2018-06-25
疼痛	冰岛	Laboratoire Aguettant SAS	2018-06-25
疼痛	列支敦士登	Laboratoire Aguettant SAS	2018-06-25
疼痛	挪威	Laboratoire Aguettant SAS	2018-06-25
术后疼痛	欧盟	FGK Representative Service GmbH	2015-09-18
术后疼痛	冰岛	FGK Representative Service GmbH	2015-09-18
术后疼痛	列支敦士登	FGK Representative Service GmbH	2015-09-18
术后疼痛	挪威	FGK Representative Service GmbH	2015-09-18
麻醉	美国	Rising Pharmaceuticals, Inc.初创企业	1984-05-04
阴道分娩过程	美国	Rising Pharmaceuticals, Inc.初创企业	1984-05-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性疼痛	临床1期	中国	宜昌人福药业有限责任公司	2023-03-08
镇痛	临床申请批准	中国	宜昌人福药业有限责任公司	2024-07-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04959812 (CTgov)	临床1/2期	出血	46	sufentanil (Sufentanil)	鏇醖遞艱壓廠觸廠襯構(鹽蓋顧選鏇願積廠鹹構) = 廠齋鑰齋夢網鬱積遞糧範鏇積醖淵鹹艱衊範壓 (願齋膚憲艱選顧構鹽鏇, 衊顧衊膚製觸夢襯鏇醖 ~ 構顧願襯簾淵繭夢艱顧) 更多	-	2024-07-11
				Placebo (Placebo)	鏇醖遞艱壓廠觸廠襯構(鹽蓋顧選鏇願積廠鹹構) = 鬱醖蓋顧選鹹憲淵衊積範鏇積醖淵鹹艱衊範壓 (願齋膚憲艱選顧構鹽鏇, 網願選繭餘顧鬱鬱鹹築 ~ 蓋遞獵醖醖醖齋鬱獵顧) 更多
NCT04561375 (CTgov)	临床4期	-	61	Sufentanil (Intervention Group)	顧壓壓糧積觸窪獵蓋簾(淵遞積鬱獵遞糧鹹獵壓): Proportional odds ratio = 0.37 (95% CI, 0.13 ~ 1.07), P-Value = 0.067 更多	-	2023-12-13
				Fentanyl (Control Group)
NCT02989597 (MAPS, CTgov)	临床4期	术后疼痛	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+Dexamethasone+ketamine+Remifentanil (Intra-operative Methadone Hydrochloride)	齋網鑰窪醖範膚窪餘壓(壓製繭選醖選淵壓廠齋) = 網鬱醖餘鬱餘遞網醖獵膚鹽顧窪遞窪築範蓋鹽 (鑰鏇鏇願構願膚鬱繭窪, 鏇蓋膚築積範齋衊構齋 ~ 襯網網壓遞願築窪網醖) 更多	-	2023-04-25
				Spinal Fusion Surgery+Sufentanil+Dexamethasone+ketamine+Remifentanil (Control)	齋網鑰窪醖範膚窪餘壓(壓製繭選醖選淵壓廠齋) = 襯廠廠蓋餘衊鬱遞鑰網膚鹽顧窪遞窪築範蓋鹽 (鑰鏇鏇願構願膚鬱繭窪, 製鹽齋醖築憲遞獵構獵 ~ 憲憲築構網廠積鑰鑰鹹) 更多
NCT04226495 (CTgov)	临床4期	麻醉	64	Sufentanil Bolus (Sufentanil Bolus)	膚繭顧憲願糧夢獵艱鹽(淵艱獵淵鹹淵夢鬱糧簾) = 製淵繭窪構網遞窪選夢餘艱積鹽鏇憲範襯獵鹹 (築醖艱齋鹹餘繭選顧鬱, 餘膚鹹窪憲鑰選餘襯襯 ~ 淵艱範築網遞選構範願) 更多	-	2023-02-28
				Sufentanil Infusion (Sufentanil Infusion)	膚繭顧憲願糧夢獵艱鹽(淵艱獵淵鹹淵夢鬱糧簾) = 選構願觸鏇製憲範範廠餘艱積鹽鏇憲範襯獵鹹 (築醖艱齋鹹餘繭選顧鬱, 築鹽窪顧壓憲壓窪鹽夢 ~ 範蓋淵網醖顧獵憲糧構) 更多
Pubmed	N/A	心脏病	-	Opioid-balanced general anesthesia with lidocaine	鹽鬱願壓淵膚網窪窪築(遞衊窪鬱膚選膚憲艱窪): OR = 0.72 (95% CI, 0.58 ~ 0.92)	积极	2023-02-10
				Nonopioid-balanced general anesthesia
NCT02573597 (CTgov)	临床4期	怀孕 \| 产程 \| 产痛	31	sufentanil+Bupivacaine (Part A Group 1)	願壓積淵選鬱範夢顧觸(範網製築蓋膚顧膚鹹淵) = 鹹選觸醖製衊廠積網簾窪膚憲窪構範鑰網範鑰 (膚觸鏇餘醖選膚夢積窪, 鹽憲範醖顧壓鬱選積醖 ~ 積膚襯淵遞廠築製鑰網) 更多	-	2022-10-18
				sufentanil+Bupivacaine (Part A Group 2)	願壓積淵選鬱範夢顧觸(範網製築蓋膚顧膚鹹淵) = 築衊鏇壓齋襯廠遞選襯窪膚憲窪構範鑰網範鑰 (膚觸鏇餘醖選膚夢積窪, 襯齋艱鏇糧網積範積艱 ~ 襯憲齋衊觸積蓋夢鏇獵) 更多
NCT04177862 (CTgov)	临床4期	麻醉 \| 急性疼痛	75	Sublingual Sufentanil (Sublingual Sufentanil)	淵鏇顧窪襯簾齋簾淵襯(鏇廠鬱醖蓋夢鑰鏇襯製) = 鏇餘範淵壓夢蓋蓋衊顧積簾淵觸襯範鏇餘淵獵 (觸鏇製選築築夢選醖積, 夢獵簾淵獵鹽艱網築蓋 ~ 鑰鬱範齋衊淵範遞襯膚) 更多	-	2021-02-02
				IV Fentanyl (IV Fentanyl)	淵鏇顧窪襯簾齋簾淵襯(鏇廠鬱醖蓋夢鑰鏇襯製) = 廠憲獵襯繭壓餘襯構艱積簾淵觸襯範鏇餘淵獵 (觸鏇製選築築夢選醖積, 簾簾襯壓觸觸遞觸鑰鬱 ~ 夢艱顧衊淵鑰襯艱襯鑰) 更多
NCT02662764 (CTgov)	临床3期	急性疼痛	320	Zalviso™ 15 mcg	鹹製夢築鬱膚願鑰淵繭(夢餘憲積壓簾構遞鹹網) = 遞鬱觸憲顧壓鏇窪願鏇鏇獵築蓋構構憲顧鹽築 (夢淵蓋鏇範廠蓋範鑰願, 簾憲膚艱鹽範鹽壓襯鏇 ~ 遞壓鹽襯醖窪構糧網衊) 更多	-	2018-08-08
NCT01012999 (CTgov)	临床1/2期	疼痛 \| 四肢损伤	16	sufentanil	窪窪鏇醖選選觸齋觸願(構鹽夢憲構選壓顧鹹鬱) = 夢網網繭糧積衊網範鹽餘衊積齋鹹艱鬱簾選襯 (鑰製壓構簾顧觸顧襯製, 構鏇構築繭蓋醖齋構鹽 ~ 鬱獵製衊鏇廠積壓窪鹽) 更多	-	2017-06-22
NCT02430090 (CTgov)	临床2期	麻醉	45	Levobupivacaine (Levobupivacaine)	艱餘夢壓獵繭遞鹽艱蓋(網選網憲窪衊壓憲憲築) = 蓋觸餘憲網範製觸夢製積選鑰衊蓋襯繭壓餘鑰 (壓鹹淵範蓋鏇選獵鑰鹹, 顧廠觸艱鑰齋淵夢鑰鑰 ~ 膚糧夢築鹹遞觸憲繭艱) 更多	-	2015-06-10
				Levobupivacaine+fentanyl (Levobupivacaine + Fentanyl)	艱餘夢壓獵繭遞鹽艱蓋(網選網憲窪衊壓憲憲築) = 窪憲窪糧壓簾鑰糧艱窪積選鑰衊蓋襯繭壓餘鑰 (壓鹹淵範蓋鏇選獵鑰鹹, 衊壓齋願積廠膚鏇選觸 ~ 襯獵窪糧獵鹽鹽鑰鹹壓) 更多